Arix Bioscience PLC Fundamentals Datasheet and Stock Analysis
Arix Bioscience plc is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. Its principal activity is to source, finance and develop healthcare and life science businesses across the world. The Company focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company holds interests in BioMotiv, OptiKira LLC, Autolus, Depixus SAS, Verona Pharma plc and Artios Pharma Ltd. The Company has agreements with universities in the United Kingdom, Europe and Australia, providing direct access to new technologies. It also has access to a range of research projects from the United States academic institutions. Its subsidiaries include Arix Bioscience Holdings Limited, Arix US Inc and Arthurian Life Sciences GP Limited.
- Current Price:105.50p
- Industry:Financials
- Sector:Financial Services
- ISIN:GB00BD045071
- Market Sector:MAIN
- Main Indices:N/A
- Country of register:Great Britain
- Currency:N/A
- Shares in Issue:136m
- Market Cap:£140m
- Date Listed:17/02/2017
Loading...
Activity Data Not Available
Non-Executive Director: Giles Kerr, Arthur Pappas Mark Breuer Non-Executive Chairman: Jonathan Peacock Executive Chairman: Naseem Amin Group Finance Director: Marcus Karia Independent Non-Executive Director: Trevor Jones Chief Scientific Officer: Graeme Smith
- Registrars:
- Address:20 Berkeley Square, London
- Phone:
- Website:http://www.arixbioscience.com
Composite Ranking: 30Historic EPS Ranking: 36Forecast EPS Ranking: 34Price Relative Strength: Industry Strength: ASMR Ranking: DROCE Ranking: DAccumulation/Dist: EMkt Accumulation/Dist: CUnbroken Annual EPS: EUnbroken Interim EPS: EPEG Current Ranking: APEG Forecast Ranking: APE Current Ranking: APE Forecast Ranking: AMargin Current Ranking: AMargin Forecast Ranking: H
| 2016 | 2017 | 2018E | 2019E | 2020E | |||
|---|---|---|---|---|---|---|---|
| Day/Month | 31/12 | 31/12 | 31/12 | 31/12 | 31/12 | ||
| Revenue | £m | 0.64 | 1.86 | £m | 1.13 | (24.40) | 0.35 |
| Operating Profit/(loss) | £m | (8.30) | (3.59) | £m | 0.00 | 0.00 | 0.00 |
| Profit Before Tax | £m | (9.53) | (7.69) | £m | 47.25 | (71.10) | 22.75 |
| Profit After Tax | £m | (8.84) | (7.47) | £m | 0.00 | 0.00 | 0.00 |
| Profit After Tax (from discontinued operations) | £m | 0.00 | 0.00 | £m | 0.00 | 0.00 | 0.00 |
| Overall Profit for the Period | £m | (8.84) | (7.47) | £m | 0.00 | 0.00 | 0.00 |
| EPS Growth | % | 0.00 | 0.00 | % | 0.00 | 0.00 | 0.00 |
| Earnings Per Share | p | (0.36) | (0.11) | p | 0.34 | (0.24) | 0.08 |
| Op. Cash Flow P/S | p | 0.00 | (11.16) | £ | 0.00 | 0.00 | 0.00 |
| Cash Flow P/S Grth | % | 0.00 | 0.00 | % | 0.00 | 0.00 | 0.00 |
| Net Cash Flow P/S | p | 0.00 | 0.00 | £ | 0.00 | 0.00 | 0.00 |
| Capital Exp P/S | £ | 0.00 | 0.00 | £ | 0.00 | 0.00 | 0.00 |
| Tax Rate | % | 0.00 | 0.00 | % | 0.00 | 0.00 | 0.00 |
| P/E Ratio | x | 0.00 | 0.00 | x | 414.70 | 0.00 | 1,337.70 |
| P/E Growth | £ | 0.00 | 0.00 | £ | 0.00 | 0.00 | 0.00 |
| Turnover Per Share | £ | 0.00 | 0.00 | £ | 0.00 | 0.00 | 0.00 |
| Pre-Tax Profit / Share | £ | 0.00 | 0.00 | £ | 0.00 | 0.00 | 0.00 |
| Operating Margin | % | (1,296.88) | (193.01) | % | 0.00 | 0.00 | 0.00 |
| ROCE | % | 0.00 | (8.73) | % | 0.00 | 0.00 | 0.00 |
| ROE | % | 0.00 | (7.75) | % | 0.00 | 0.00 | 0.00 |
| Mkt Cap | £m | 0.00 | 262.91 | £m | 0.00 | 0.00 | 0.00 |
| Dividend Per Share | p | 0.00 | 0.00 | p | 0.00 | 0.00 | 0.00 |
| DPS Growth | % | 0.00 | 0.00 | % | 0.00 | 0.00 | 0.00 |
| Dividend Yield | % | 0.00 | 0.00 | % | 0.00 | 0.00 | 0.00 |
| Dividend Cover | x | 0.00 | 0.00 | x | 0.00 | 0.00 | 0.00 |
| Shareholder Funds | £m | 46.33 | 146.44 | £m | 0.00 | 0.00 | 0.00 |
| Net Borrowings | £m | (28.93) | (74.94) | £m | 0.00 | 0.00 | 0.00 |
| Net Assets | £m | 46.33 | 146.44 | £m | 0.00 | 0.00 | 0.00 |
| Net Assets P/S | £ | 0.00 | 0.00 | £ | 0.00 | 0.00 | 0.00 |
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | 0.0% | 0.0% |
| Op Margin | 115.7% | 6,500.0% |
| ROCE | 0.0% |
| Traded | Action | Notifier | Price | Amount | Value |
|---|---|---|---|---|---|
| 20-Mar-18 | Buy | Jonathan Peacock | 225.00p | 90,000 | £,202,500 |
| 20-Mar-18 | Buy | Jonathan Peacock | 225.00p | 90,000 | £202,500 |
| 02-Jun-17 | Buy | Joseph Anderson | 206.10p | 55,000 | £113,355.01 |
| 02-Jun-17 | Buy | Joseph Anderson | 2.06p | 55,000 | £113,355.01 |
| 02-Jun-17 | Buy | Jonathan Peacock | 2.06p | 28,016 | £57,740.98 |
| 02-Jun-17 | Buy | Jonathan Peacock | 206.10p | 28,016 | £57,740.98 |
| 02-Jun-17 | Buy | James Rawlingson | 2.06p | 26,000 | £53,586 |
| 02-Jun-17 | Buy | James Rawlingson | 206.10p | 26,000 | £53,586 |
| 08-May-17 | Buy | James Rawlingson | 202.39p | 11,484 | £23,242.47 |
| 08-May-17 | Buy | James Rawlingson | 2.02p | 11,484 | £23,242.47 |
| Notifier | Holding | Value |
|---|---|---|
| Jonathan Peacock | 129,500 | ˆ,622.50 |
| Arthur Pappas | 47,619 | 2,238.04 |
| Mark Breuer | 36,630 | &,644.65 |
| Giles Kerr | 35,746 | %,712.03 |
| Trevor Jones | 9,535 | ,059.42 |
| News Title | Date | Time | Source |
|---|---|---|---|
| Harpoon presents interim Phase 1 data for HPN424 | 29-May-20 | 13:38 | PRN |
| Autolus presents additional AUTO3 data in DLBCL | 29-May-20 | 13:06 | PRN |
| Second Price Monitoring Extn | 27-May-20 | 16:40 | RNS |
| Price Monitoring Extension | 27-May-20 | 16:35 | RNS |
| Amplyx closes $53 million Series C extension | 20-May-20 | 07:00 | PRN |
| Notice of Annual General Meeting | 12-May-20 | 07:00 | PRN |
| Pharmaxis announces new data in myelofibrosis | 28-Apr-20 | 09:23 | PRN |
| Harpoon doses first patient in multiple myeloma trial | 27-Apr-20 | 13:12 | PRN |
| Director/PDMR Shareholding | 17-Apr-20 | 14:59 | PRN |
| Autolus announces FDA acceptance of IND application | 16-Apr-20 | 13:08 | PRN |